The local medical community is abuzz with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor showing impressive results in early trials for managing obesity. This therapy suggests a https://socialmediastore.net/story22934367/retatrutide-australia-a-emerging-hope-for-obesity-treatment